Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
Completed · Phase 3 · Has a placebo group
Conditions studied: Chronic Obstructive Pulmonary Disease (COPD)
In brief
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will be up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast. For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).
Key facts
- Study ID
- NCT00297115
- Run by
- AstraZeneca
- People needed
- 1568
- Starts
- 2006-03-01
- Expected to finish
- 2008-08-01
- Last updated by the study team
- 2016-11-07
Who can join
Age: 40 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Altana Pharma/Nycomed Investigational Site — Birmingham, Alabama, United States
- Altana Pharma/Nycomed Investigational Site — Birmingham, Alabama, United States
- Altana Pharma/Nycomed Investigational Site — Huntsville, Alabama, United States
- Altana Pharma/Nycomed Investigational Site — Bullhead City, Arizona, United States
- Altana Pharma/Nycomed Investigational Site — Phoenix, Arizona, United States
- Altana Pharma/Nycomed Investigational Site — Phoenix, Arizona, United States
- Altana Pharma/Nycomed Investigational Site — Fort Smith, Arkansas, United States
- Altana Pharma/Nycomed Investigational Site — Little Rock, Arkansas, United States
- Altana Pharma/Nycomed Investigational Site — Anaheim, California, United States
- Altana Pharma/Nycomed Investigational Site — Burbank, California, United States
- Altana Pharma/Nycomed Investigational Site — Carlsbad, California, United States
- Altana Pharma/Nycomed Investigational Site — Fresno, California, United States
- Altana Pharma/Nycomed Investigational Site — Lakewood, California, United States
- Altana Pharma/Nycomed Investigational Site — Long Beach, California, United States
- Altana Pharma/Nycomed Investigational Site — Los Alamitos, California, United States
- Altana Pharma/Nycomed Investigational Site — Los Angeles, California, United States
- Altana Pharma/Nycomed Investigational Site — Roseville, California, United States
- Altana Pharma/Nycomed Investigational Site — Sacramento, California, United States
- Altana Pharma/Nycomed Investigational Site — San Diego, California, United States
- Altana Pharma/Nycomed Investigational Site — San Diego, California, United States
- Altana Pharma/Nycomed Investigational Site — Sepulveda, California, United States
- Altana Pharma/Nycomed Investigational Site — Stockton, California, United States
- Altana Pharma/Nycomed Investigational Site — Denver, Colorado, United States
- Altana Pharma/Nycomed Investigational Site — Waterbury, Connecticut, United States
- Altana Pharma/Nycomed Investigational Site — Bayou La Batre, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.